Trends in pediatric melanoma mortality in the United States, 1968 through 2004

Kevan G Lewis1

  • 1Department of Dermatology, Brown Medical School/Rhode Island Hospital, Providence, Rhode Island 02903, USA. kglewis@brown.edu

Insights

Pediatric melanoma mortality in the U.S. is low but substantial. Despite rising incidence, childhood melanoma deaths declined from 1968-2004, particularly in older children and white males.

Area of Science:

  • Dermatology
  • Public Health
  • Epidemiology

Background:

  • Pediatric melanoma mortality is poorly understood, with limited research.
  • Childhood melanoma presents a significant public health challenge.

Purpose of the Study:

  • To characterize pediatric melanoma mortality in the United States.
  • To evaluate trends in childhood melanoma deaths over time.

Main Methods:

  • Utilized U.S. Center for National Health Statistics death certification records (1968-2004).
  • Analyzed data on age, race, gender, and geographic location for children under 20.

Main Results:

  • 643 pediatric melanoma deaths occurred over 37 years (avg. 18/year).
  • Mortality rates were higher in older children (15-19), males, and white children.
  • Overall pediatric melanoma mortality showed a steady decline from 1968 to 2004.

Conclusions:

  • Childhood melanoma mortality, while low, represents a considerable public health burden.
  • Trends suggest falling mortality rates in children and adolescents, contrasting with rising incidence.
  • Further research is needed to reduce childhood melanoma mortality.
Abstract

Related Concept Videos

Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Changes in Skin Color: Clinical Perspectives01:14

Changes in Skin Color: Clinical Perspectives

The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...